Companies whose breakthroughs revolutionize industries often end up being massively successful. Think 's move from DVDs to streaming, or Apple's innovative smartphone that killed BlackBerry's competing franchise.

Could Recursion Pharmaceuticals (NASDAQ: RXRX) experience similar success? The biotech is, after all, working hard to introduce a major paradigm shift in the industry. Let's find out what exactly Recursion is working on, and whether buying the company's shares is worth it.

The process of developing novel medicines is notoriously complicated, expensive, and long. Though you might think it's getting faster and cheaper thanks to technological breakthroughs, the opposite is true. This phenomenon is known as Eroom's law (the reverse of Moore's law), the observation that the drug discovery process is slowing down and becoming more costly.

Continue reading

Source Fool.com